Following publication of today’s IQVIA Report Assessing Person-Centered Therapeutic Innovations, EFPIA is calling for the inclusion of patient experience and patient preferences in Health Technology Assessment (HTA) evaluation and pricing and reimbursement decisions. Person-centered therapeutic innovations can have a significant and tangible impact on patients’ quality of life, improve adherence and as a consequence improve outcomes. Yet the report, indicates that many HTA bodies and payers do not consider person-centered therapeutic innovations meaningfully in their evaluation of new treatments.
Jean-Christophe Tellier, EFPIA President said. “We believe that the inclusion of the improvement of patient experience and patient preferences in HTA evaluation and pricing and reimbursement decisions is necessary. Person-centered therapeutic innovations can have a significant and tangible impact on patients’ quality of life, improve adherence and as a consequence improve outcomes.”
The IQVIA report, commissioned by EFPIA, outlined the significant difference between how payers and end users (patients & clinicians) perceive the value of person-centered therapeutic innovations. The report found that many payers and HTA bodies often overlook the added value of such innovations. In fact, many HTA bodies do not consider patient experience benefits in their own right, favoring a more singular focus on clinical outcomes.
David Haerry from the European Aids Treatment Group (EATG) has welcomed the report and called it a wake-up call: “HTA processes stand today where regulators found themselves twenty years ago - isolated from natural stakeholders and partners who have to cope with the consequences of their decision making. This report should be a wake-up call.”
The white paper can be accessed here.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.